Michelle Prickett, MD
Pulmonary Disease · Chicago, ILNPI 1821259995
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $34,133 of the $39,983 with a category attached, or 85.4%. 12 manufacturers reported payments, led by Insmed, Inc. at 52.5% of the total. 2025 is the largest year on record at $25,417, more than ten times the $102 reported in 2019. Among pulmonary disease clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $799.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$21K
- BD$14K
- Baxter Healthcare$4K
- AbbVie$184
- Viatris Specialty LLC$136
- Advanced Respiratory, Inc$47
- plus $126 from 6 others
Across 153 payments — averaging $1064.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$128K
- Vertex$35K
What the payments were for
- Consulting fees$34,13385%
- Travel & lodging$9402%
- Food & beverage$7102%
- Education$4,20011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 16 | $20,990 |
| BD | 17 | $14,300 |
| Baxter Healthcare | 1 | $4,200 |
| AbbVie(2 entities) | 8 | $184 |
| Viatris Specialty LLC | 1 | $136 |
| Advanced Respiratory, Inc | 1 | $47 |
| Hill-rom Company, Inc | 1 | $28 |
| Melinta Therapeutics, LLC | 1 | $27 |
| Sanofi | 1 | $24 |
| Philips North America LLC | 1 | $23 |
| GSK | 1 | $13 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hillrom - Volara System$4,200
- TOBI Podhaler$136
How this compares
$39,983 in reported general payments places this provider in the 90th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 16 | $487,602 |
| CaystonAztreonam Lysine | 14 | $164,958 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $105,755 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $13,847 |
| Spiriva RespimatTiotropium Bromide | 21 | $12,045 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $9,071 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $8,711 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,487 |
| DuleraMometasone/Formoterol | 13 | $5,011 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $3,630 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 93 | $2,744 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,055 |
| Ventolin HfaAlbuterol Sulfate | 25 | $1,611 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $1,448 |
| Azithromycin | 91 | $1,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $13 | $21,38940 claims |
| AstraZenecaSymbicort | $12 | $8,71134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Chicago
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
- Manu JainChicago$187K
- Richard WunderinkChicago$178K
- Rade TomicChicago$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.